Table 3.
Tacrolimus- vs. cyclosporine-treated group: baseline characteristics.
Overall N = 128 (100) |
Tacrolimus N = 42 (33) |
Cyclosporine N = 86 (67) |
p-value | |
---|---|---|---|---|
Baseline characteristics | ||||
Age, years | 53 [43, 60] | 55 [42, 61] | 52 [44, 60] | 0.401 |
M, n (%) | 82 (64) | 25 (60) | 57 (66) | 0.502 |
F, n (%) | 46 (36) | 17 (40) | 29 (34) | |
BMI, kg/m2 | 23 [20, 27] | 24 [20, 27] | 23 [21, 27] | 0.999 |
Corticosteroids, n (%) | 72 (56) | 18 (43) | 54 (63) | 0.040 |
O2 therapy, n (%) | 115 (90) | 36 (86) | 79 (92) | 0.350 |
Diabetes, n (%) | 23 (18) | 10 (24) | 13 (15) | 0.230 |
Chronic renal disease, n (%) | 2 (2) | 0 (0) | 2 (2) | 0.999 |
Oto score | 3 [1, 5] | 3 [2, 5] | 3 [1, 5] | 0.201 |
LAS | 36 [33, 40] | 38 [34, 45] | 35 [33, 39] | <0.001 |
Underlying diseases * | ||||
Septic, n (%) | 29 (23) | 9 (21) | 20 (23) | 0.010 |
Interstitial, n (%) | 65 (51) | 26 (62) | 39 (45) | |
Obstructive, n (%) | 23 (18) | 7 (17) | 16 (19) | |
Others, n (%) | 11 (9) | 0 (0) | 11 (13) | |
Previous colonization | ||||
Recipient-related, n (%) | 41 (32) | 12 (29) | 29 (34) | 0.600 |
None, n (%) | 87 (68) | 30 (71) | 57 (66) | |
Provenience | ||||
Hospital, n (%) | 8 (6) | 4 (10) | 4 (5) | |
Home, n (%) | 120 (94) | 38 (90) | 82 (95) | 0.400 |
Data are expressed median [I-III quartile] for continuous variables and absolute numbers (percentage) for categorical ones. * Septic: cystic fibrosis, bronchiectasis; Interstitial: idiopathic pulmonary fibrosis, allergic extrinsic alveolitis, non-specific interstitial pneumonia, fibrosing emphysema, lymphocytic interstitial pneumonia, respiratory bronchiolitis interstitial lung; Obstructive: chronic obstructive pulmonary disease, emphysema; Others: idiopathic pulmonary hypertension, veno-occlusive disease, connective tissue disease, α1-anti-tripsin deficiency, lymphangioleiomyomatosis, histiocytosis, sarcoidosis, graft versus host disease. Abbreviations: BMI, body mass index; F, female; LAS, lung allocation score; LT, lung transplantation; M, male; n, number.